長春高新(000661.SZ):金賽藥業擬斥5203.55萬元投資杭州沃維醫療獲其68%股權 涉足新生兒腦發育領域
格隆匯12月22日丨長春高新(000661.SZ)公佈,公司子公司金賽藥業擬與杭州沃維醫療科技有限公司(簡稱“杭州沃維醫療”)及其現有股東就收購杭州沃維醫療68%股權事項共同簽署《杭州沃維醫療生物科技有限公司增資擴股及股權轉讓協議》。
該次收購主要系金賽藥業以其自有資金擬分階段以增資擴股並收購原股東部分股權的形式,合計收購杭州沃維醫療68%的股權(其中由金賽藥業或/及金賽藥業指定的第三方以增資擴股形式認購杭州沃維醫療10%股權)。根據杭州沃維醫療相關產品取得《醫療器械註冊證》的進度,該次投資總額預期合計約5203.55萬元人民幣。
目前,公司在新生兒領域進行佈局,此次公司通過新生兒腦發育相關產品進入該領域,符合腦發育研究的國家科技戰略,與公司在兒童期的神經精神、老年退行性疾病領域相關業務呼應,有助於公司未來在腦科學領域佔有一席之地。
杭州沃維醫療圍繞腦疾病和腦智發育領域,主要着眼於新生兒及成人腦功能監護設備註冊開發,其研發的2款監護設備技術成熟,已處於註冊階段,正式上市後將有利於對新生兒的腦功能狀態(包括腦損傷和腦發育)實施有效監控。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.